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Abstract
Hypoxia induces a myriad of changes including an increase in hematocrit due to erythropoietin (EPO) mediated
erythropoiesis. While hypoxia is of importance physiologically and clinically, lacunae exist in our knowledge of the systemic
and temporal changes in gene expression occurring in blood during the exposure and recovery from hypoxia. To identify
these changes expression profiling was conducted on blood obtained from cohorts of C57Bl-10 wild type mice that were
maintained at normoxia (NX), exposed for two weeks to normobaric chronic hypoxia (CH) or two weeks of CH followed by
two weeks of normoxic recovery (REC). Using stringent bioinformatic cut-offs (0% FDR, 2 fold change cut-off), 230 genes
were identified and separated into four distinct temporal categories. Class I) contained 1 transcript up-regulated in both CH
and REC; Class II) contained 202 transcripts up-regulated in CH but down-regulated after REC; Class III) contained 9
transcripts down-regulated both in CH and REC; Class IV) contained 18 transcripts down-regulated after CH exposure but
up-regulated after REC. Profiling was independently validated and extended by analyzing expression levels of selected
genes as novel biomarkers from our profile (e.g. spectrin alpha-1, ubiquitin domain family-1 and pyrroline-5-carboxylate
reductase-1) by performing qPCR at 7 different time points during CH and REC. Our identification and characterization of
these genes define transcriptome level changes occurring during chronic hypoxia and normoxic recovery as well as novel
blood biomarkers that may be useful in monitoring a variety of physiological and pathological conditions associated with
hypoxia.
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Introduction
Since the pioneering studies of Paul Bert, Denis Jourdanet and
Francois-Gilbert Viault conducted in late 1800, it is well known
that hypoxia, due to reduced oxygen tension noted at high
altitude, is a primary physiological stimulus for erythrocyte
production in both animals and humans [1,2]. Early in the 20
th
century, Carnot and De Flandre suggested the existence of a
humoral agent that responds to hypoxia and induces erythropoi-
esis [3]. Later, several experiments demonstrated that plasma
contains the humoral agent erythropoietin (EPO) capable of
inducing hematopoiesis during hypoxic and anemic conditions [4].
In 1977, Miyake et al. purified EPO from human urine samples
[5], which facilitated its cloning and consequently the production
of recombinant EPO used nowadays to treat certain types of
anemia [6]. Under hypoxic conditions, kidney and liver are the
major sites of EPO production and bone marrow is the major
target. EPO acts synergistically with granulocyte-macrophage
colony-stimulating factor, stem cell factor, and interleukins 3, 4
and 9 as well as insulin growth factor-1 in the later stages of
erythropoiesis. Along with EPO, other cytokines and growth
factors induce proliferation, maturation and survival first in the
burst forming unit-erythroid and then in the colony forming unit-
erythroid. The final result is an increase of reticulocytes which can
be measured in the peripheral blood stream, and consequently an
increase in the number of mature erythrocytes and hematocrit [6].
The molecular mechanism of hypoxia-induced over-expression
of EPO remained elusive until 1995 when Wang & Semenza [7]
described hypoxia inducible factor (HIF). HIF belongs to the PAS
family of transcription factors and consists of an oxygen-sensitive a-
subunit and anoxygeninsensitive b-subunit. Three a-subunits have
been described for HIF (21a, 22a, and 23a), which under
normoxia are rapidly targeted by the von Hippel-Lindau tumor
suppressor or prolyl-hydroxylation and subsequently degraded.
Under hypoxic conditions, HIF-1a and HIF-2a stabilize and
heterodimerizewithHIF-btoformHIFandthusinitiateamultistep
pathway of activation that includes nuclear translocation and
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2recruitment of transcriptional co-activators, to act as a transcrip-
tionalregulatoratthehypoxia-responseelement(HRE)bindingsite
for the hypoxia-sensitive enhancer located in the 39 Untranslated
Region (UTR) of the gene [8]. The action of HIF is limited to short
periods of hypoxia and its stabilization is tissue-dependent. Mice
exposed to a FiO2 of 6% present different kinetics of HIF
stabilization for brain, kidney and liver. In the brain, the peak of
stabilization occurs after 4–5 hours of hypoxia, returning to
normoxic levels after 9–12 hours of hypoxia. In kidney and liver,
thepeakofHIFoccursafter1–2hours,returningtonormoxiclevels
after3hoursexposuretohypoxia[9].HIFmRNAlevelsfrombrain,
kidney and liver exposed to hypoxic conditions remain unchanged
compared to normoxic conditions [9], supporting the hypothesis of
post-translational degradation.Theseresults suggest thatin vivo HIF
is important to regulate acute systemic and local responses, such as
regional changes in blood supply, but may not play a major role in
the acclimatization to chronic hypoxia [9,10].
The hypoxia-induced gene expression mechanism is present in
almost all types of cells inducing metabolic and structural changes
according to the tissue type, tissue requirements and intensity of
the hypoxic challenge. More than 80 possible HIF-target genes
from several pathways have been described [11]. Although there is
an extensive list of genes that respond to hypoxia, only the EPO
receptor, CD36 (marker for early erythroid cells) and c-globin [12]
have been suggested and used as biomarkers for hypoxia-induced
erythropoiesis in blood cells. While obtaining whole blood sample
is an easy and fast technique, the lack of additional biomarkers
makes it difficult to differentiate between acute and chronic
hypoxia exposure as well as from normoxic recovery stages. To
address this, we used microarray analysis to identify changes in
gene expression occurring in the peripheral blood cells of mice
exposed to chronic hypoxia and normoxic recovery to study their
gene expression levels. We independently validated the transcrip-
tome changes by qPCR and have identified three novel blood
biomarkers based on these transcriptome levels changes.
Methods
Animals
All animal experiments were approved by the Institutional
Animal Care and Use Committee (permit number 80888) of the
University of Pennsylvania School of Medicine. Adult normal
(C57Bl/10) mice aged 3 months were obtained from Jackson
Laboratory (Jackson Laboratory, Bar Harbor, Maine, USA).
Hypoxic exposure was undertaken in a specially designed,
hermetically closed hypoxic chamber using the Pegas 4000 MF
gas mixing system (Columbus Instruments, Ohio USA). The
oxygen level was gradually decreased from 21% to 8% (Table 1).
The weights of the animals were monitored daily and food and
water were offered ad libitum. In Protocol 1 (Figure 1A), mice were
randomly divided into three groups for gene expression profiling:
normoxic (NX), chronic hypoxic (CH) and recovery (REC); each
group consisted of 4 animals. The groups were exposed for 14 days
to NX (NX; group 1), 14 days to CH (CH; group 2) and 14 days to
CH followed by 14 days of normoxia (REC; group 3). In Protocol
2 (Figure 1B) five mice were randomly selected from each group to
one of the seven day points (NX-0, CH-1, CH-3, CH-7, CH-14,
REC-7 and REC-14). All animals used in both protocols 1 and 2
presented similar initial body weight.
RNA Isolation for Microarray Hybridization
Intravenous blood was collected and approximately 50 mLo f
blood was used for hematocrit measurement and the rest
(c. 750 mL) was saved in RNALater (Qiagen, Valencia, CA,
USA) for further analysis. Total RNA was isolated from blood
samples using Tri-Reagent (Ambion, Austin, TX, USA) as
described by the manufacturer. Isolated total RNA was cleaned
up by RNeasy mini kit (Qiagen, Valencia, CA, USA) according to
the manufacturer’s instructions. The purity and concentration of
total RNA were determined by measurement of absorbance at 260
and 280 nm using a Nanodrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). To satisfy our
purity criteria, we required that all RNA.
samples used in our experiments had a 260/280 ratio between
1.8 and 2.1. RNA integrity was monitored by determining
the28S/18S ratio using an Agilent 2100 Bioanalyzer (Agilent
Technologies Inc., Santa Clara, CA, USA).
Linear Amplification and cRNA Labeling for Microarray
Hybridization
Three microliter total RNA was used for each sample to obtain
linearly amplified labeled cRNA by using GeneChipH One-Cycle
Target Labeling kit (Affymetrix, Santa Clara, CA, USA) as
described by the manufacturer. Briefly; total RNA was used to
generate double-stranded cDNA with the T7-oligo (dT) primer.
This double-stranded cDNA was used for in vitro transcription
and biotin labeling steps. Labeled cRNA yield and purity were
determined by measuring the absorbance at 260 and 280 nm. All
the cRNA 260/280 ratios were between 1.9 and 2.1. Quality
control of the labeled cRNA products was assessed by performing
gel electrophoresis using 1 mg labeled cRNA on a 2% agarose gel.
Fragmentation and Microarray Hybridization
Fifteen micrograms labeled cRNA extracted from NX, CH and
REC samples were fragmented and 10 mg were hybridized to
AffymetrixH Mouse 430 ver. 2.0 GeneChip arrays for 18–24 hrs
(Affymetrix Inc.). Each microarray was washed and stained with
streptavidin–phycoerythrin and scanned at a 6-mm resolution with
an Agilent model G2500A GeneArray scanner. A visual quality
control measurement was performed to ensure proper hybridiza-
tion after each chip was scanned. Other quality control parameters
such as scaling factors used to normalize the chips, average
background, and noise were also evaluated. In addition, raw
intensities for each probe set were stored in electronic formats by
the GeneChip Operating System version 1.1 (GCOS1.1, Affyme-
trix Inc.). Primary data is accessible in the GEO database
(Accession number GSE 17728).
Data was normalized using the GC-RMA algorithm in Partek
Genome Suite (Partek Incorporate, St Louis, MO). Differentially
expressed transcripts were identified at the level of two fold change
cut-off and 0% FDR. Differentially expressed transcripts were
clustered using the functional annotation clustering tool of the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) program [13,14].
Validation of Gene Expression by qPCR
Real time quantitative polymerase chain reaction (qPCR) was
used to measure the relative expression level of mRNA of four
genes (spectrin alpha-1, ubiquitin domain family-1, pyrroline-5-
carboxylate reductase-1 and CD-36) in five independent blood
samples harvested from animals exposed to Protocol 2 (Figure 1B).
Briefly, 100 ng of RNA was extracted from blood, reversed
transcribed in 20 mL final reaction using random hexamers and
the SuperScript First-Strand Synthesis according to the manufac-
turer (Invitrogen, Carlsbad, CA). Two ng of cDNA was amplified
in 20 mL of reaction mixtures containing 1 pmole of forward and
reverse primers each, 10 mLo f2 6TaqMan universal PCR master
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performed in a 7900HT Sequence Detection System (ABI).
Samples were run in triplicates.
Hematocrit Measurement and Reticulocyte Counting in
Peripheral Blood
Hematocrit was measured using blood collected in heparinized
micro-hematocrit capillary tubes (Fisher, Pittsburgh, PA) and
centrifuged for two minutes using an International micro-
capillary centrifuge model MB. Two measurements were made
for each animal and the average value was calculated.
Reticulocyte counts were performed on thick blood films made
using 300 mL of peripheral blood collected in a syringe with
30 mL EDTA 0.5 M as anti-coagulant. The wedge method was
used for making the blood film [15]. Brilliant Cresyl blue
supravital staining was performed according to manufacturer’s
protocols (ENG Scientific, Clifton, NJ; Catalog number 5111).
The number of erythrocytes and reticulocytes were manually
counted using a microscope at 1006 magnification and
reticulocyte percentage was calculated [15].
Results
Expression Profile
To identify and define gene expression changes that occur in
peripheral blood during hypoxia and normoxic recovery,
expression profiling was conducted on blood obtained from
cohorts of C57Bl-10 wild type mice. The animals were
maintained either at normoxia (NX), exposed for two weeks
to normobaric chronic hypoxia (CH) or two weeks of CH
followed by two weeks normoxic recovery (REC) as described in
Protocol 1 (Figure 1). Out of the 45,101 probe sets present on
the array, 512 probe sets (representing equal numbers of
transcripts) showed significant (p,0.05 after multiple testing
correction) differential expression across the three experimental
conditions (NX, CH, REC) upon the application of ANOVA, a
0% FDR and a twofold change cut-off. Out of these probe sets,
230 transcripts showed a significant differential expression in
both CH and REC conditions (Supplemental Table S1).
Heatmap analysis (Figure 2) demonstrates the relative changes
in transcript expression of two weeks of CH exposure and two
weeks of CH followed by two weeks of REC (Protocol 1,
Figure 1A). These results were compared to two weeks of
exposure to NX (control conditions). The differential clustering
of the samples, visually observed in the heatmap was confirmed
by principal component analysis (PCA). The CH samples are
more dispersedly distributed, but still significantly different from
control and recovery samples. PCA axes 1, 2 and 3 were
49.7%, 12.9% and 9.05%, respectively.
The 230 transcripts were classified into four different
categories according to their expression in CH and during
REC (Figure 3). The first quadrant (I) contained one transcript
that was up-regulated in both CH and REC conditions; the
second quadrant (II) contained 202 genes up-regulated in CH
followed by down-regulated expression after two weeks of REC;
the third quadrant (III) contained 9 transcripts that were down-
regulated during both CH and REC; the fourth quadrant (IV)
showed 18 transcripts that were down-regulated in CH exposure
followed by up-regulated expression after two weeks of REC.
Only the genes contained in the second quadrant reached the
minimum number to enable meaningful functional annotation
clustering analysis using DAVID [13,14]. The significantly
enriched clusters revealed processes related to cellular catabolic
processes, followed by metabolic processes and hematopoiesis
(Supplemental Table S2).
Figure 1. Protocols for molecular signature and validation. A. Animals were divided into three groups of 5 mice each. Group 1 was exposed
to normoxia (NX) for two weeks; group 2 exposed to two weeks of NX and then two weeks of chronic hypoxia (CH); group 3 was exposed to two
weeks of NX, followed by two weeks of CH and another two weeks of normoxic recovery (REC). B. Protocol 2 was designed to test the expression
levels of differentially expressed genes from the microarray analysis. Each day point corresponds to a group of five mice exposed to normoxia (NX-0),
chronic hypoxia (CH-1, CH-3, CH-7 and CH-14) and recovery (REC-7 and REC-14).
doi:10.1371/journal.pone.0037497.g001
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Reticulocytes
In order to study more precisely the effects of chronic hypoxia
and recovery during normoxia over time and to correlate these
with changes in gene expression, we designed a second protocol,
in which we weighed the animals and harvested peripheral blood
samples at 7 different day points (NX-0, CH-1, CH-3, CH-7,
CH-14, REC-7 and REC-14; Figure 1B). Figure 4A shows the
decreasing FiO2 levels during protocol 2, namely CH from 21%
down to 8% and then the recovery at 21%. The average body
weight (BW) decreased during CH exposure (Figure 4B),
reaching the minimum at CH-14 (Table 3). However, the BW
rapidly recovered from CH returning to similar levels as NX-0 at
REC-7. Hematocrit significantly increased at CH-7, reaching its
maximum level at CH-14 (Table 3). After return to normoxia,
the hematocrit remained significantly above NX-0 levels until
REC-7 (Figure 4C), returning to a normal level on REC-14. The
relative amount of reticulocytes significantly increased at CH-7
(Table 3), and correlated to the first significant rise of the
hematocrit on CH-7 rather than at day 14 of CH when the
hematocrit peaked.
Validation of Gene Expression by qPCR and
Characterization of Potential Biomarkers for CH and REC
In order to independently validate our profiling as well as to
extend our studies toward identifying novel biomarkers in
peripheral blood from mice challenged to CH and REC, we
selected three candidate genes detected in our microarray study:
spectrin a-1 (Spna1), ubiquitin family domain containing 1
(Ubfd1) and pyrroline-5-carboxylate reductase 1 (Pycr1). We
performed qPCR analyses on independent samples taken from
Table 1. Protocol for CH and REC.
Day FiO2 (%) Microarray Biomarker
NX-0 21 NN
CH-1 15 N
CH-2 13
CH-3 12 N
CH-4 11
CH-5 10
CH-6 9
CH-7 8 N
CH-8 10
CH-9 9
CH-10 9
CH-11 9
CH-12 8
CH-13 8
CH-14 8 NN
REC-1 21
REC- 2 21
REC-3 21
REC-4 21
REC-5 21
REC-6 21
REC-7 21 N
REC-8 21
REC-9 21
REC-10 21
REC-11 21
REC-12 21
REC-13 21
REC-14 21 NN
Protocol used for Microarray profile (Protocol 1) and Biomarker (Protocol 2)
experiments. The N indicates the peripheral blood harvest from 5 different
animals. The fraction of inspiration (FiO2) was changed every 24 hours.
doi:10.1371/journal.pone.0037497.t001
Table 2. List of genes used for validation of gene expression.
Name
TAQMANH Gene Expression
Assay ID REFSEQ
CD36 Mm00432403_m1 NM_001159557.1
Spna1 Mm00501882_m1 NM_011465.4
Ubfd1 Mm01165153_m1 NM_138589.2
Pycr1 Mm00522674_m1 NM_144795.3
Actb Mm00607939_s1 NM_007393.3
Name, TAQMAN catalog number from Applied BiosystemsH and REFSEQ from
each gene used on validation of microarray study. The last gene is the
housekeeping gene used.
doi:10.1371/journal.pone.0037497.t002
Figure 2. Heatmap and dendrogram representations of all 512
transcripts that were differentially expressed in CH and REC.
Each column represents one sample (chip) and each row a differentially
expressed transcript. The intensity of the transcript expression is
indicated by the gray shaded bar at the right side of the figure. The four
chronic hypoxia (CH) and recovery (REC) GeneChip data sets cluster into
two distinct groups based on correlation of gene expression pattern.
The dendrogram branches lengths for CH and REC sub-trees seen at the
top are based on normalized raw data of all transcripts and
quantitatively demonstrate that the four samples are closely related
to each other. Each horizontal bar represents one probe set, and the
intensity of gray color of the bar determines the degree of expression.
doi:10.1371/journal.pone.0037497.g002
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and CH-14 during hypoxia exposure and at REC-7 and REC-
14 (Protocol 2, Figure 1B). To correlate the expression of our
set of genes with the hematopoietic response to hypoxia, we also
studied the gene expression level of CD36, a known marker for
erythroid progenitors [12]. The fold changes were compared to
levels at day 0 (Table 4). As shown in Figure 5, CD36 levels
significantly increased its expression level only at CH-7,
reaching its maximum at CH-14; once returned to normoxic
conditions the expression of CD36 decreased significantly and
remained down-regulated at REC-14 (Figure 5A). The expres-
sion of Spna1 increased significantly one day earlier than CD36,
i.e. at CH-3 and remained up-regulated during CH exposure;
nevertheless, during REC the expression of Spna1 decreased,
reaching the lowest level at REC-14 (Figure 5B). As predicted
by the microarray profile, the expression of Ubfd1 was
significantly below normoxic levels during the entire period of
CH exposure and remained down-regulated over the 2 weeks of
REC (Figure 5C). Finally, consistent with the microarray
predictions, Pycr1 expression showed an early response with a
significant increase at CH-3 and remained up-regulated
throughout CH exposure until REC-14 (Figure 5D).
Discussion
Our goal in this study was to identify the systemic and temporal
changes in gene expression occurring in blood during the exposure
and recovery from hypoxia to identify novel genes to be used as
possible reference genes (biomarkers) detectable by qPCR in small
samples of peripheral blood. Since all blood cells were used rather
than sorted by cell types, we cannot attribute contribution of gene
changes to specific peripheral blood cell type or types, and thus
discuss the changes in gene expression and analyses as an effect of
CH present in the whole peripheral blood.
Out of 230 differentially regulated transcripts found to be
differentially regulated, we did not identify any differentially
expressed transcripts from the list of 86 HIF-regulated genes
that have been detected in a stringent meta-analysis across 6 cell
types [11]. However, we did identify 5 genes differentially
expressed in liver from mice exposed to CH [10] (solute carrier
family 16, B-cell translocation gene 3, testis-specific protein; Y-
encoded-like 1, CD36 antigen and preimplantation protein 4).
Another comparison of our differentially regulated genes with a
set of genes derived from bone marrow of mice exposed to
intermittent hypoxia also revealed only 15 genes to be in
common as shown in Supplemental Table S3 [16]. These
comparisons show that HIF may not directly regulate the
expression of our 230 transcripts during CH and support the
evidence that while HIF is important during the acute phase
response during hypoxia to regulate local and systemic
mechanisms that underpin oxygen sensing [9,10], it may not
play a major role in the chronic phase of acclimatization to
CH. However, comparisons with 11 other studies who have
studied the effects of hypoxia across different species and tissues
using differing experimental protocols for hypoxia exposure
Figure 3. Fold change relationship of differential gene expression. The 230 differentially expressed genes were divided into four different
sets according to their expression over time. The abscissa represents the fold change of the CH transcript expression profile, and the ordinate
represents the fold change of the REC transcript expression profile. The first quadrant (I) shows one gene (circle) up-regulated in both CH and REC.
The second quadrant (II) shows the 202 genes (square) up-regulated during CH and down-regulated after REC. The third quadrant (III) shows the 9
genes (triangle) down-regulated in both CH and REC conditions. The fourth quadrant (IV) shows 18 genes (diamond) which are down-regulated
during CH and up-regulated after REC.
doi:10.1371/journal.pone.0037497.g003
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suggesting its specificity to tissue type and condition studied
[17,18,19,20,21,22,23,24,25,26,27].
As a systemic response for acclimatization to CH, we observed a
significant loss of BW over the period of CH exposure, reaching its
lowest level at the end of the CH protocol (CH-14), confirming
previous reports [28]. However, during recovery, the BW rapidly
recovered to similar levels as before CH exposure. Hypoxia-
induced BW loss has been extensively reported [28,29,30,31,32].
The mechanisms involving BW loss are thought to be mediated
mainly by carbohydrate and lipid metabolisms. The glucose
metabolism has been extensively studied and is considered a major
energy pathway involved in the response to hypoxia [8]. Subjects
lost weight and did not increase their blood sugar level despite
drinking 100 grams of glucose after a 17 days-expedition to the
Chilean Andes exposed to high altitude (5340 MASL) [33]. CH
induces the expression of glucose transporter (GLUT) types 1 and
4 in rat cardiac and skeletal muscles [29,32] and GLUT1 in the
brain blood barrier [30], suggesting that the lower plasma glucose
induced by CH leads to higher expression and activity of GLUT in
several tissues. Finally, hypoxia inhibits liver gluconeogenesis,
subsequent to a reduction in phosphoenolpyruvate carboxykinase
activity [34]. Together, these results suggest that the loss of BW
during CH exposure may be attributed to increased carbohydrate
catabolism.
A novel mechanism for BW regulation during hypoxia may
involve the leptin pathway, which is a regulator of BW and lipid
metabolism during hypoxia. Leptin is an obese (ob) gene product
and its mature form contains a 167 amino-acid peptide hormone
[35]. It is produced in adipose tissue [36], placenta [37], stomach
[38], muscle tissue [39], and cerebral adenohypophysis and
hypothalamus [40]. The action of leptin is mediated by 6 different
isoforms of the receptor present in the hypothalamus [41,42],
regulating BW by suppressing food intake and increasing the
energy expenditure, glucose and fatty acid metabolism, hemato-
poiesis and immune system [43,44,45,46]. The ob gene contains a
HRE site that can be bound by HIF in its 59-untranslated region
Figure 4. Effect of CH and REC on body weight, hematocrit and
reticulocytes. A. FIO2 was reduced from 21% to 8% (CH) over a two
week period, to return to 21% for two weeks (REC). B. Body weight (BW)
was reduced during CH and rapidly returned to a normal level during
REC. C. Hematocrit increased during CH and returned to normal levels
after 14 days of REC. D. Relative amount of reticulocytes increased until
day 7 of CH and then returned to normoxic levels (NX) during REC.
Mean 6 SEM; n=5 per day point. * p.0.05; ** p.0.01; *** p.0.001,
relative to NX-0.
doi:10.1371/journal.pone.0037497.g004
Table 3. Body weight and hematological response to CH and
recovery exposures.
Day FiO2 (%) BW (g) Hematocrit (%) Reticulocytes (%)
NX-0 21 26.9460.21 40.8060.20 11.7660.90
CH-1 15 26.6260.22 44.9060.94 9.1360.62
CH-3 13 25.8860.30 46.3061.61 13.3361.05
CH-7 8 24.1260.42 54.8060.12** 21.2662.05*
CH-14 8 23.3860.44 * 71.1062.20*** 15.6261.07
REC-7 21 27.3060.46 54.5861.19** 9.7762.68
REC-14 21 31.6460.59 43.9461.51 10.1761.49
Values in Mean 6 SEM. Significant differences compared to day 0.
*p,0.05.
**p,0.01.
***p,0.001.
doi:10.1371/journal.pone.0037497.t003
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challenges [47,48]. Recently, Baze et al. showed that chronic
exposure to hypobaric hypoxia (4500 MASL) increases the leptin
receptor expression in liver samples [10]. In concordance with
those results, rats exposed during 90 days at 5500 MASL showed
an increase of lipid metabolism in both liver and skeletal muscle
[49]. These results suggest that fatty acid catabolism, hematopoi-
esis and energy expenditure are important factors for acclimati-
zation to hypoxia and that the leptin pathway may play a
profound role as a part of the mechanism for BW regulation noted
during CH acclimatization.
We observed that CH and REC treatments had significant
effects on classical peripheral blood parameters. The hematocrit
level increased from 40% at NX to 54% and 74% at CH-7 and
CH-14, respectively. The levels of hematocrit from CH-14 only
returned to similar levels of NX-0 normal levels after 14 days of
REC. Interestingly, the hematocrit at REC-7 presented similar
levels as CH-7, suggesting that the turnover of erythrocytes is
similar during the waxing and waning of hematopoeisis during CH
and REC. It is well established that hypoxia induces EPO
expression under either physiological or pathophysiological
conditions, resulting in an increase of reticulocyte, hematocrit
and hemoglobin concentration [1,50]. While the relative numbers
of reticulocytes were noted to be increased at CH-3 compared to
NX-0, the increase became significant at CH-7, but did not
continue to increase after 14 days of CH compared to CH-7.
Rather, the expression level decreased, but still remained above
normoxic level. The percentage of reticulocytes showed similar
levels as at NX-0 once returned to REC. Our results are in
concordance with studies performed in humans exposed to either
intermittent or continuous CH (7 days, FiO2 15.4%) which
reported an increase of the relative amount of reticulocytes on the
5
th and 7
th day [51]. The hypoxia-induced increase in reticulocytes
is also known to occur during prolonged hypoxic exposure. After a
21-day expedition to the Andes with continuous exposure above
4000 MASL (maximum of 6768 MASL), subjects submitted to
four hours in a hypobaric chamber (4500 MASL, 443 mmHg)
showed a new increase in the number of reticulocytes, as well as in
the percentage of red blood cells [31]. This result shows the
capacity of colony forming unit-erythroid to response to new
hypoxic challenge and continue to form new reticulocytes. [31].
This hypoxia-mediated reticulocytosis phenomenon has also been
reported in animals, with a slightly different time-course response.
A study using rats exposed to a hypobaric hypoxia protocol (21
days at 0.5 atm; PB 380 mm Hg) showed an increase in the
relative number of reticulocytes on day 3, reaching the maximum
on day 7, before returning to normal levels on day 14. However,
the reticulocytes reached a new peak on day 21 of the protocol
[52]. These results suggest a negative feedback on the hypoxia-
induced reticulocytes formation, which reaches its maximum after
5–7 days of hypoxia before decreasing to normal levels, as we have
described here.
One of the major aims of our study was to analyze the
expression profile to identify and validate novel genes that could
be used as reference genes (biomarkers) of CH and REC.
Towards this goal we studied the expression levels of Spna1,
Ubfd1 and Pycr1 as well as the previously characterized CD36
gene expression in detail. The pattern of differential expression of
Spna1 paralleled changes in hematocrit during CH and REC,
while Ubdf1 and Pycr1 genes were down- and up-regulated
respectively, during the CH and REC periods. CD36 is a
88 KDa cell surface protein that belongs to an evolutionary
conserved Class B scavenger receptors family [53,54]. The
expression of CD36 in erythroid cells is limited to reticulocytes,
Figure 5. Expression of whole peripheral blood biomarkers
exposed to chronic hypoxia. Real time qPCR was normalized using
the expression of b-actin as a housekeeping control. A. CD36 as a
marker for erythropoiesis increased the expression level during chronic
hypoxia (CH), but decreased below normoxic levels during REC. B.
Spna1 presented a similar pattern as CD36, by increasing its gene
expression level during CH and decreasing it below normoxic levels
after REC. C. Ubfd1 remained down-regulated during the entire
protocol of CH and REC. D. CH up-regulated Pycr1 which remained
up-regulated for 14 days of REC. Mean 6 SEM; n=5 per day point.
*p .0.05; ** p.0.01; *** p.0.001 Relative to NX-0.
doi:10.1371/journal.pone.0037497.g005
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marker for early erythroid cells [12]. Acute hypoxia up-regulates
CD36 in intrapulmonary arteries via activation of HRE
mediated by HIF [57,58]. In our microarray analysis, CD36
was up-regulated in mice peripheral blood during CH (fold-
change 16.65) and then down-regulated during REC (fold-
change -2.85). This pattern of expression was confirmed by
qPCR in our extended time-point protocol 2, showing a
significant increase in CD36 expression already after day 2 of
CH and a marked down-regulation upon return to normoxia.
The significant increase partially overlapped with the increased
relative amount of reticulocytes on CH-7. This difference may be
explained by the proliferation of reticulocytes induced by hypoxia
[59]. Nevertheless, the expression of CD36 was completely
suppressed by REC, suggesting that reticulocyte proliferation
activity was also reduced during REC.
Spna1 is a 280 KDa subunit of the spectrin cytoskeletal protein
[60,61,62,63]. Spectrin is a major constituent of red blood cell
membranes and responsible for resistance to mechanical stress,
cellular form and anchors for other proteins such as hemoglobin
receptors and channels [64,65]. Our results suggest that in whole
blood samples, Spna1 expression is increased in response to CH.
However its expression level declined during REC reaching NX
levels, paralleling changes in hematocrit.
Ubfd1 is a novel polyubiquitin binding protein [66]. Although
hypoxia-induced changes in expression have not previously been
described, analysis of primary data (GEO number GDS1807) in a
study using a human lymphocyte cell line exposed to FiO2 0.1%
for 29 hours demonstrated down-regulation of two transcripts
(224878_at and 20568_at) of this gene [67]. These data are in
agreement with our demonstration that Ubfd1 expression is
sensitive to CH and remained significantly down-regulated from
the beginning of the hypoxic exposure until several days after the
REC.
Pycr1 is a mitochondrial enzyme that converts pyrroline-5-
carboxilic acid into proline in a NAD(P)H-dependent reaction
[68]. Pycr1 generates an oxidizing potential to stimulate the
metabolism of glucose through the hexose monophosphate-
pentose pathway and the Embden-Meyerhof pathway, an
important pathway in erythrocytes [69]. The increase of Pycr1
expression during CH suggests an increase of erythrocyte
metabolism and glucose consumption in order to increase the
amount of NAD(P)
+, not limiting the production of ATP via the
anaerobic pathway of glycolysis. In astrocytes, 24 hours of hypoxia
up-regulates Pycr1 expression and has been shown to be mediated
by p53 [70]. In our profile, Pycr1 expression increased upon CH
challenge, increased its expression further during CH and
remained above the normoxic expression level even after 14 days
of REC.
In conclusion, we describe the molecular signature for whole
peripheral blood samples from mice challenged to CH and REC.
The expression profile of genes separable into four distinct
temporal categories (I-IV) using our criteria offers novel
biomarkers to monitor a variety of physiological and pathological
conditions associated with exposure to hypoxia and during
recovery. While methods such as pulse oximetry or blood gas
analysis are accurate and useful for detecting hypoxia as it
occurs, they present limited utility in terms of being able to
report prior occurrence of hypoxia or indeed recovery from prior
hypoxic exposure. In contrast to using increased hematocrit
levels as a marker for prior hypoxia exposure, the suggested
gene-based biomarkers may be able to distinguish between
chronic hypoxia and recovery from hypoxia with greater
accuracy and independent of clinical states that often accompany
hypoxia (e.g. volume dysregulation) which may falsely alter
hematocrit levels. We believe that the novel biomarkers described
here may be used to detect prior hypoxic exposure of up to 2
weeks duration either in isolation or as a combination (e.g. from
Categories II & IV) analogous to the manner in which HbA1c is
used to report the average blood glucose level over the previous
month rather than just at the time of the test while managing
patients with Diabetes. We believe that these potential novel
biomarkers will be of great benefit to the research community
and clinicians as it enables the detection of hypoxia in a post
hypoxic state. However, we think it will be important to test the
biomarkers identified here in a variety of animal models and
clinical settings prior to their utilization.
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Table 4. Gene expression response to CH and REC exposure.
Day CD36 Spna1 Ubdf1 Pycr1
CH-1 21.1860.13 1.3960.29 25.4460.04 (0.002) 1.4560.37
CH-3 1.2060.25 3.0460.67 (0.015) 26.0460.04 (0.001) 3.7660.90 (0.008)
CH-7 2.4660.48 (0.012) 5.8461.28 (0.001) 25.9160.04 (0.001) 4.3661.54 (0.002)
CH-14 9.7662.38 (0.001) 4.5660.93 (0.001) 29.6960.10 (0.001) 32.3167.00 (0.001)
REC-7 28.0060.04 (0.001) 24.0260.09 26.4760.05 (0.001) 5.7162.11
REC-14 210.9760.02 (0.002) 210.4660.03 (0.033) 211.7560.03 (0.018) 8.6262.54
Fold changes values compared to Day 0 (NX-0). Values are in Mean 6 SEM. Significant p-values are shown in brackets.
doi:10.1371/journal.pone.0037497.t004
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